Literature DB >> 17021110

Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa.

Anna R Thorner1, Ronald Vogels, Jorn Kaspers, Gerrit J Weverling, Lennart Holterman, Angelique A C Lemckert, Athmanundh Dilraj, Lisa M McNally, Prakash M Jeena, Soren Jepsen, Peter Abbink, Anjali Nanda, Patricia E Swanson, Andrew T Bates, Kara L O'Brien, Menzo J E Havenga, Jaap Goudsmit, Dan H Barouch.   

Abstract

We assessed neutralizing antibody titers to adenovirus serotype 5 (Ad5) and six rare adenovirus serotypes, serotypes 11, 35, 50, 26, 48, and 49, in pediatric populations in sub-Saharan Africa. We observed a clear age dependence of Ad5-specific neutralizing antibody titers. These data will help to guide the development of Ad vector-based vaccines for human immunodeficiency virus type 1 and other pathogens.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17021110      PMCID： PMC1594810          DOI： 10.1128/JCM.01249-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  13 in total

1.  Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors.

Authors:  Mieke C Sprangers; Wandena Lakhai; Wouter Koudstaal; Marielle Verhoeven; Björn F Koel; Ronald Vogels; Jaap Goudsmit; Menzo J E Havenga; Stefan Kostense
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

2.  Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States.

Authors:  Edward Nwanegbo; Eftyhia Vardas; Wentao Gao; Hilton Whittle; Huijie Sun; David Rowe; Paul D Robbins; Andrea Gambotto
Journal:  Clin Diagn Lab Immunol       Date:  2004-03

3.  Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5.

Authors:  Lennart Holterman; Ronald Vogels; Remko van der Vlugt; Martijn Sieuwerts; Jos Grimbergen; Jorn Kaspers; Eric Geelen; Esmeralda van der Helm; Angelique Lemckert; Gert Gillissen; Sandra Verhaagh; Jerome Custers; David Zuijdgeest; Ben Berkhout; Margreet Bakker; Paul Quax; Jaap Goudsmit; Menzo Havenga
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

4.  Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.

Authors:  Angelique A C Lemckert; Shawn M Sumida; Lennart Holterman; Ronald Vogels; Diana M Truitt; Diana M Lynch; Anjali Nanda; Bonnie A Ewald; Darci A Gorgone; Michelle A Lifton; Jaap Goudsmit; Menzo J E Havenga; Dan H Barouch
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

5.  Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.

Authors:  Diane M Roberts; Anjali Nanda; Menzo J E Havenga; Peter Abbink; Diana M Lynch; Bonnie A Ewald; Jinyan Liu; Anna R Thorner; Patricia E Swanson; Darci A Gorgone; Michelle A Lifton; Angelique A C Lemckert; Lennart Holterman; Bing Chen; Athmanundh Dilraj; Angela Carville; Keith G Mansfield; Jaap Goudsmit; Dan H Barouch
Journal:  Nature       Date:  2006-04-16       Impact factor: 49.962

6.  Replication-defective vector based on a chimpanzee adenovirus.

Authors:  S F Farina; G P Gao; Z Q Xiang; J J Rux; R M Burnett; M R Alvira; J Marsh; H C Ertl; J M Wilson
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

7.  Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein.

Authors:  Shawn M Sumida; Diana M Truitt; Angelique A C Lemckert; Ronald Vogels; Jerome H H V Custers; Marylyn M Addo; Shahin Lockman; Trevor Peter; Fred W Peyerl; Michael G Kishko; Shawn S Jackson; Darci A Gorgone; Michelle A Lifton; Myron Essex; Bruce D Walker; Jaap Goudsmit; Menzo J E Havenga; Dan H Barouch
Journal:  J Immunol       Date:  2005-06-01       Impact factor: 5.422

Review 8.  Factors determining prevalence of maternal antibody to measles virus throughout infancy: a review.

Authors:  V M Cáceres; P M Strebel; R W Sutter
Journal:  Clin Infect Dis       Date:  2000-07-25       Impact factor: 9.079

9.  A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.

Authors:  Julie C Fitzgerald; Guang-Ping Gao; Arturo Reyes-Sandoval; George N Pavlakis; Zhi Q Xiang; Anthony P Wlazlo; Wynetta Giles-Davis; James M Wilson; Hildegund C J Ertl
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

Review 10.  Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors.

Authors:  John W Shiver; Emilio A Emini
Journal:  Annu Rev Med       Date:  2004       Impact factor: 13.739
View more
  58 in total

1.  Optimized adenovirus-antibody complexes stimulate strong cellular and humoral immune responses against an encoded antigen in naive mice and those with preexisting immunity.

Authors:  Jin Huk Choi; Joe Dekker; Stephen C Schafer; Jobby John; Craig E Whitfill; Christopher S Petty; Eid E Haddad; Maria A Croyle
Journal:  Clin Vaccine Immunol       Date:  2011-11-16

2.  Identification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors.

Authors:  Joseph T Bruder; Ping Chen; Elena Semenova; Charlie A Thomas; Svetlana Konovalova; Greg Ekberg; Damodar Ettyreddy; Duncan McVey; Jason G Gall; C Richter King; Douglas E Brough
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

3.  Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization.

Authors:  Cheng Cheng; Jason G D Gall; Martha Nason; C Richter King; Richard A Koup; Mario Roederer; M Juliana McElrath; Cecilia A Morgan; Gavin Churchyard; Lindsey R Baden; Ann C Duerr; Michael C Keefer; Barney S Graham; Gary J Nabel
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

Review 4.  Respiratory syncytial virus vaccine development.

Authors:  Julia L Hurwitz
Journal:  Expert Rev Vaccines       Date:  2011-10       Impact factor: 5.217

5.  Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors.

Authors:  Issa Nébié; Nick J Edwards; Alfred B Tiono; Katie J Ewer; Guillaume S Sanou; Issiaka Soulama; Souleymane Sanon; Amidou Diarra; Jean Baptiste Yaro; David Kangoye; Egeruan B Imoukhuede; Adrian V S Hill; Sodiomon B Sirima
Journal:  Clin Vaccine Immunol       Date:  2014-04-16

6.  Longevity of adenovirus vector immunity in mice and its implications for vaccine efficacy.

Authors:  Ekramy E Sayedahmed; Rashmi Kumari; Shruti Shukla; Ahmed O Hassan; Sulma I Mohammed; Ian A York; Shivaprakash Gangappa; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Vaccine       Date:  2018-09-25       Impact factor: 3.641

7.  International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations.

Authors:  Dan H Barouch; Sandra V Kik; Gerrit J Weverling; Rebecca Dilan; Sharon L King; Lori F Maxfield; Sarah Clark; David Ng'ang'a; Kara L Brandariz; Peter Abbink; Faruk Sinangil; Guy de Bruyn; Glenda E Gray; Surita Roux; Linda-Gail Bekker; Athmanundh Dilraj; Hannah Kibuuka; Merlin L Robb; Nelson L Michael; Omu Anzala; Pauli N Amornkul; Jill Gilmour; John Hural; Susan P Buchbinder; Michael S Seaman; Raphael Dolin; Lindsey R Baden; Angela Carville; Keith G Mansfield; Maria G Pau; Jaap Goudsmit
Journal:  Vaccine       Date:  2011-05-25       Impact factor: 3.641

8.  Frequent detection of human adenovirus from the lower gastrointestinal tract in men who have sex with men.

Authors:  Marcel E Curlin; Meei-Li Huang; Xiaoyan Lu; Connie L Celum; Jorge Sanchez; Stacy Selke; Jared M Baeten; Richard A Zuckerman; Dean D Erdman; Lawrence Corey
Journal:  PLoS One       Date:  2010-06-25       Impact factor: 3.240

9.  Infection and killing of multiple myeloma by adenoviruses.

Authors:  Julien S Senac; Konstantin Doronin; Stephen J Russell; Diane F Jelinek; Philip R Greipp; Michael A Barry
Journal:  Hum Gene Ther       Date:  2010-02       Impact factor: 5.695

10.  Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans.

Authors:  Kara L O'Brien; Jinyan Liu; Sharon L King; Ying-Hua Sun; Joern E Schmitz; Michelle A Lifton; Natalie A Hutnick; Michael R Betts; Sheri A Dubey; Jaap Goudsmit; John W Shiver; Michael N Robertson; Danilo R Casimiro; Dan H Barouch
Journal:  Nat Med       Date:  2009-07-20       Impact factor: 53.440
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.